Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia
Updates to Article Attributes
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is an extremely rare pulmonary disorder at the benign end of the neuroendocrine cells proliferation spectrum. It is mainly seen in non-smoker middle-age females with a history of chronic cough or asthma. On imaging, it is characterised by several nodules and extensive mosaic attenuation. It is, however, recognised with increasing frequency.
Epidemiology
DIPNECH typically occurs in middle-to-late age, and there isThere may be an increased female predilection 3,10. Most patients tend to be non-smokers.10
Clinical presentation
Most are asymptomatic, where discovery is made incidentally on thoracic imaging for an unrelated reason. Some, however, may present with symptoms such as an insidious cough, a or a slowly progressive dyspnoea, or an asthma-like presentation 7,10.
Pathology
It is characterised by a generalised proliferation of scattered single cells, small nodules or linear proliferations of pulmonary neuroendocrine cells (enterochromaffin cells, "Kulchitsky cells") 9. It is sometimes considered to be a precursor to pulmonary carcinoid tumours.
Radiographic features
CT
Various features have described, each of which is non-specific on their own. These include:
- small lung nodules
with: considered alower zone and peripheral predominance: mostgenerally frequent feature 3,4,10-4 - ground-glass changes3
-
mosaic perfusion pattern 6
,7,10-7: due to air trapping -
bronchial wall thickening 7
,10 - mucus plugging
-
bronchiectasis 3,7
,10: generally mild
Treatment and prognosis
The rarity of the condition poses some clinical challenge in establishing treatment and assessing prognosis. Limited studies suggest that the condition can have a variable prognosis ranging from clinical improvement to being stable to rare clinical deterioration 5. Various treatment strategies have been described which include somatostatin analoguessystemic and inhaled corticosteroids, azithromycinbronchodilators, and lung transplantation resection.10
History and etymology
The first clinical series of six cases describing DIPNECH was published by Aguayo et al. in 1992.11
-<p><strong>Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH)</strong> is an extremely rare pulmonary disorder at the benign end of the neuroendocrine cells proliferation spectrum. It is mainly seen in non-smoker middle-age females with a history of chronic cough or <a href="/articles/asthma-1">asthma</a>. On imaging, it is characterised by several nodules and extensive mosaic attenuation. It is, however, recognised with increasing frequency.</p><h4>Epidemiology</h4><p>DIPNECH typically occurs in middle-to-late age, and there is an increased female predilection <sup>3,10</sup>. Most patients tend to be non-smokers <sup>10</sup>.</p><h4>Clinical presentation</h4><p>Most are asymptomatic, where discovery is made incidentally on thoracic imaging for an unrelated reason. Some, however, may present with symptoms such as an insidious cough, a slowly progressive dyspnoea, or an asthma-like presentation <sup>7,10</sup>.</p><h4>Pathology</h4><p>It is characterised by a generalised proliferation of scattered single cells, small nodules or linear proliferations of pulmonary neuroendocrine cells (enterochromaffin cells, "Kulchitsky cells") <sup>9</sup>. It is sometimes considered to be a precursor to <a href="/articles/pulmonary-carcinoid-tumours">pulmonary carcinoid tumours</a>.</p><h4>Radiographic features</h4><h5>CT</h5><p>Various features have described, each of which is non-specific on their own. These include:</p><ul>-<li>small <a href="/articles/pulmonary-nodule-1">lung nodules</a> with a lower zone and peripheral predominance: most frequent feature <sup>3,4,10</sup> </li>- +<p><strong>Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH)</strong> is an extremely rare pulmonary disorder at the benign end of the neuroendocrine cells proliferation spectrum. It is mainly seen in non-smoker middle-age females with a history of chronic cough or <a title="Asthma" href="/articles/asthma-1">asthma</a>. On imaging, it is characterised by several nodules and extensive mosaic attenuation. It is, however, recognised with increasing frequency.</p><h4>Epidemiology</h4><p>There may be an increased female predilection <sup>3</sup>. Most patients tend to be non-smokers.</p><h4>Clinical presentation</h4><p>Most are asymptomatic, where discovery is made incidentally on thoracic imaging for an unrelated reason. Some, however, may present with symptoms such as an insidious cough or a slowly progressive dyspnoea <sup>7</sup>.</p><h4>Pathology</h4><p>It is characterised by a generalised proliferation of scattered single cells, small nodules or linear proliferations of pulmonary neuroendocrine cells (enterochromaffin cells, "Kulchitsky cells") <sup>9</sup>. It is sometimes considered to be a precursor to <a href="/articles/pulmonary-carcinoid-tumours">pulmonary carcinoid tumours</a>.</p><h4>Radiographic features</h4><h5>CT</h5><p>Various features have described, each of which is non-specific on their own. These include:</p><ul>
- +<li>small <a href="/articles/pulmonary-nodule-1">lung nodules</a>: considered a generally frequent feature <sup>3-4</sup> </li>
-<a href="/articles/mosaic-attenuation-pattern-in-lung">mosaic perfusion pattern</a> <sup>6,7,10</sup>: due to air trapping</li>-<li>-<a href="/articles/bronchial-wall-thickening">bronchial wall thickening</a> <sup>7,10</sup>- +<a href="/articles/ground-glass-opacification-3">ground-glass changes</a> <sup>3</sup>
-<a href="/articles/bronchiectasis">bronchiectasis</a> <sup>3,7,10</sup>: generally mild</li>-</ul><h4>Treatment and prognosis</h4><p>The rarity of the condition poses some clinical challenge in establishing treatment and assessing prognosis. Limited studies suggest that the condition can have a variable prognosis ranging from clinical improvement to being stable to rare clinical deterioration <sup>5</sup>. Various treatment strategies have been described which include somatostatin analogues, azithromycin, and lung transplantation <sup>10</sup>.</p><h4>History and etymology</h4><p>The first clinical series of six cases describing DIPNECH was published by <strong>Aguayo </strong>et al. in 1992 <sup>11</sup>.</p>- +<a href="/articles/mosaic-attenuation-pattern-in-lung">mosaic perfusion pattern</a> <sup>6-7</sup>: due to air trapping</li>
- +<li>
- +<a href="/articles/bronchial-wall-thickening">bronchial wall thickening</a> <sup>7</sup> </li>
- +<li><a href="/articles/mucoid-impaction-lung-1">mucus plugging</a></li>
- +<li>
- +<a href="/articles/bronchiectasis">bronchiectasis</a> <sup>3,7</sup>
- +</li>
- +</ul><h4>Treatment and prognosis</h4><p>The rarity of the condition poses some clinical challenge in establishing treatment and assessing prognosis. Limited studies suggest that the condition can have a variable prognosis ranging from clinical improvement to being stable to rare clinical deterioration <sup>5</sup>. Various treatment strategies have been described which include systemic and inhaled corticosteroids, bronchodilators, and lung resection.</p><h4>History and etymology</h4><p>The first clinical series of six cases describing DIPNECH was published by <strong>Aguayo </strong>et al. in 1992.</p>